CTC analyses by CellSearchTM (a FDA‐cleared platform for clinical testing of EpCAM+ CTCs) of these CDX models demonstrated an increased number of CTCs and tumor burden in the later generations of CDX mice (Fig. 2F). Here, EPCAM is linked to neoplasm.